Venous Thromboembolism and Cardioembolism » Atrial Fibrillation

Abstract Number: PB2086

An observational Study of INR Control and Bleeding Events, According to European Society of Cardiology (ESC) Guidelines, in Non-valvular Atrial Fibrillation (NVAF) Stratified by Male and Female Sex

D. Harris¹, F. Torabi¹, R. Alikan², A. Akbari¹, D. Mallory¹, D. Thayer¹, T. Wang¹, S. Grundy³, S. Lister⁴, M. Gravenor¹, J. Halcox¹

Abstract Number: PB2074

Anticoagulant Management Strategies in Cancer Patients with Atrial Fibrillation in Daily Clinical Practice

G. Chu¹, M.V. Huisman¹, H. Gelderblom², M.E. Hemels^3,4, T. van der Hulle², S.A. Trines⁵, F.A. Klok¹

Abstract Number: PB2055

Anticoagulation in Non-Valvular Atrial Fibrillation: Old or New Friends?

M.-A. Gaman¹, E.-C. Dobrica², M.-A. Cozma², C.C. Diaconu³

Abstract Number: PB2069

Anticoagulation Resumption After Intracerebral Hemorrhage in Two Cohorts of Patients Treated with Vitamin K Antagonists and Direct Oral Anticoagulants

D. Poli¹, E. Antonucci², E. Vignini¹, L. Martinese¹, S. Testa³, G. Guazzaloca⁴, P. Simioni⁵, V. Pengo⁵, P. Pignatelli⁶, A. Falanga⁷, L. Masciocco⁸, D. Barcellona⁹, A. Ciampa¹⁰, P. Chiarugi¹¹, C. Paparo¹², E. Bucherini¹³, M. Marzolo¹⁴, W. Ageno¹⁵, G. Palareti²

Abstract Number: PB2057

Assessment and Predictors of Inappropriate Dose of Direct Oral Anticoagulants

M. Almegren¹, M. Alotaibi², M. Alghafis², M. Al-Alwan², S. Alshehri², M. Almulla², L. Zaid²

Abstract Number: PB2080

Association of Body Mass Index (BMI) with Bleeding Events in Patients Taking Oral Anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE)

T. Feldeisen¹, X. Kong¹, E. Kline-Rogers¹, C. Alexandris-Souphis¹, B. Haymart¹, D. DeCamillo¹, S. Kaatz², M. Ali³, J. Kozlowski⁴, V. Shah⁵, G.D. Barnes¹, J.B. Froehlich¹

Abstract Number: PB2060

Association of Clinical Risk Factors and Biomarkers with Thromboembolism, Major Bleeding, and All-Cause Death in Patients with Atrial Fibrillation in a Tertiary Care Setting

D. Kraemmer, O. Königsbrügge, S. Nopp, I. Pabinger, C. Ay

Abstract Number: PB2088

Atrial Fibrillation Treated with Warfarin at an Academic Medical Center: The Potential Impact of Direct Oral Anticoagulants on Future Management

P. Collins¹, A. Lewin¹, N. Vincze Irving¹, K. Sylvester¹, J. Fanikos¹, S.Z. Goldhaber², J.M. Connors³

Abstract Number: PB2079

Beyond the Registry: A Nuanced Evaluation of Real World Anticoagulation for Nonvalvular Atrial Fibrillation Patients at a Tertiary Care Center

G. Woodhouse¹, Z. Paschall², C. Lunowa³, J. Burch¹, L. Schilling⁴, M. Rosenberg⁵, N. Mantini⁵

Abstract Number: PB2049

Characterization of VKA Control in Patients with Thrombotic and Major Hemorrhagic Events in Anticoagulation Hematology Units: Results from the EVENTHO Study

O. Gavín¹, V. Roldán², A. Santamaría³, P. Llamas⁴, D. Arumí⁵, S. Fernández de Cabo⁵

Abstract Number: PB2040

Clinical Case: Reversal of Dabigatran Levels in Patients with Renal Insufficiency that Have Required the use of Idarucizumab

A. Tugues Peiró¹, C. Marzo Alonzo¹, E. Vicente Pascual¹, A. Ferrero Campos¹, A. Ruiz¹, M.E. Rivero¹, A. Garcia Guiñon¹, A. Luaña¹, C. Chavez¹, M. Teixido¹, X. Gomez², T. Garcia¹

Abstract Number: PB2064

Clinical Outcomes for Patients of High Body Weight on Apixaban or Rivaroxaban

G. Bahra, Z. Mahir, V. Collings, K. Breen, B. Hunt, A. Cohen

Abstract Number: PB2085

Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation

M. Giustozzi¹, M. Mazzetti², M. Paciaroni¹, G. Agnelli¹, C. Becattini¹, M.C. Vedovati¹

Abstract Number: PB/LB03

Differences in Outcomes between Real-World vs Clinical Trial in Atrial Fibrillation and Chronic Kidney Disease

W.Y. Ding¹, J.M.R. Caravaca^1,2, V. Roldán³, G.Y.H. Lip^1,4

Abstract Number: PB2051

Differences in Treatment and Outcomes in Recently Diagnosed Atrial Fibrillation between the Netherlands and Belgium: Results from the GARFIELD-AF Registry

J. Seelig^1,2, M.E.W. Hemels^1,3, O. Xhaët⁴, M.C.M. Bongaerts⁵, A. de Wolf⁶, B.E. Groenemeijer⁷, A. Heyse⁸, P. Hoogslag⁹, J. Voet¹⁰, J.P.R. Herrman¹¹, G. Vervoort¹², W. Hermans¹³, B. Wollaert¹⁴, L.V.A. Boersma^15,16, K. Hermans¹⁷, A. Lucassen¹⁸, K. Pieper¹⁹, F.W.A. Verheugt¹¹, F. Cools²⁰, H. ten Cate^2,21, on behalf of the GARFIELD-AF Investigators

Abstract Number: PB2062

Differential Effect of Direct Oral Anticoagulants (DOACs) on Thrombin Generation and Clot Lysis in Patients with Non Valvular Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)

L. Dirienzo¹, A. Vitulli¹, C.T. Ammollo¹, F. Mancazzo¹, C. Dellanoce², O. Paoletti², S. Testa², M. Colucci¹

Abstract Number: PB2054

Effect of Patient and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) Study

K. MacDougall¹, J. Douketis², N. Li², N. Clark³, A. Tafur⁴, J. D'Astous⁵, J. Duncan², S. Schulman², A. Spyropoulos⁶

Abstract Number: PB2068

Emergency Room Access of Patients on DOACs: A Six Years Single Center Experience

L. Crippa¹, L. Pozzi², L. Tomassini¹, P. Della Valle¹, E. Pattarini³, A. Fattorini¹, A. D'Angelo¹

Abstract Number: PB2052

Factor V Leiden Is Associated with Atrial Fibrillation, but Not Ischemic Stroke in Atrial Fibrillation. The Tromsø Study

E.M. Hald¹, M.-L. Løchen², E.B. Mathiesen³, I. Njølstad², S.K. Brækkan¹, J.-B. Hansen¹

Abstract Number: PB2065

Fatal Intracerebral Hemorrhage in a Patient on Warfarin: A Case Report

A.B.R. Rosa¹, M.F.S. Praxedes², B.C.S. Almeida¹, A.F. Medeiros³, A.L. Ribeiro¹, M.A.P. Martins^1,4